1 min read
Add as a preferred source on GoogleGeron Returns to Quarterly Profit as Rytelo Drives Q3 Revenue Growth
Rytelo revenue growth helped reverse a run of quarterly losses. Shares rose more than 10% in early premarket trading Nov. 4.
Geron Corporation posted a quarterly profit in Q3 2026 as revenue growth from its blood cancer drug Rytelo helped reverse a run of quarterly losses. Shares gained more than 10% in early premarket trading Wednesday, Nov. 4.
Geron markets imetelstat as Rytelo. The results followed the company’s plan to end a late-stage study of the drug after efficacy concerns.
Geron shares fell more than 20% on Oct. 28. The company’s plan to stop the late-stage study followed concerns about the drug’s efficacy.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.